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Abstract 
Background: Cisplatin neuro-, oto-, and nephrotoxicity are major problems in children with malignant tumors, 
including medulloblastoma, negatively impacting educational achievement, socioemotional development, and over-
all quality of life. The blood-labyrinth barrier is somewhat permeable to cisplatin, and sensory hair cells and cochlear 
supporting cells are highly sensitive to this toxic drug. Several chemoprotective agents such as N-acetylcysteine (NAC) 
were utilized experimentally to avoid these potentially serious and life-long side effects, although no clinical phase I 
trial was performed before. The purpose of this study was to establish the maximum tolerated dose (MTD) and phar-
macokinetics of both intravenous (IV) and intra-arterial (IA) NAC in adults with chronic kidney disease to be used in 
further trials on oto- and nephroprotection in pediatric patients receiving platinum therapy.
Methods: Due to ethical considerations in pediatric tumor patients, we used a clinical population of adults with 
non-neoplastic disease. Subjects with stage three or worse renal failure who had any endovascular procedure were 
enrolled in a prospective, non-randomized, single center trial to determine the MTD for NAC. We initially aimed to 
evaluate three patients each at 150, 300, 600, 900, and 1200 mg/kg NAC. The MTD was defined as one dose level 
below the dose producing grade 3 or 4 toxicity. Serum NAC levels were assessed before, 5 and 15 min post NAC. 
Twenty-eight subjects (15 men; mean age 72.2 ± 6.8 years) received NAC IV (N = 13) or IA (N = 15).
Results: The first participant to experience grade 4 toxicity was at the 600 mg/kg IV dose, at which time the proto-
col was modified to add an additional dose level of 450 mg/kg NAC. Subsequently, no severe NAC-related toxicity 
arose and 450 mg/kg NAC was found to be the MTD in both IV and IA groups. Blood levels of NAC showed a linear 
dose response (p < 0.01). Five min after either IV or IA NAC MTD dose administration, serum NAC levels reached the 
2–3 mM concentration which seemed to be nephroprotective in previous preclinical studies.
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Background
Cisplatin is a common chemotherapeutic agent used to 
treat various types of malignant tumors. However, side 
effects such as neuro-, oto-, and nephrotoxicity limit 
the application of cisplatin. Cisplatin ototoxicity is of 
particular concern in children with malignant tumors 
where life-long hearing impairment can cause serious 
psychosocial deficits including social isolation, limited 
employment opportunities and associated earning poten-
tial, and an overall decrease in quality of life measures 
[1, 2]. The pathogenesis is not completely understood, 
but it is likely to be caused by depletion of intracellular 
glutathione (GSH) and generation of immune cell- and 
organ parenchymal-derived reactive oxygen species 
(ROS) and other free radicals [3]. Cisplatin is able to 
cross the blood-labyrinth barrier and enter the cochlea 
and sensory hair cells where it causes degeneration of 
the cochlear supporting cells, outer and inner hair cells 
and results in a progressive, irreversible hearing loss [4, 
5]. For example, in medulloblastoma where the standard 
of care treatment includes cisplatin, ototoxicity occurs 
in approximately 80–90% of children treated with stand-
ard therapy [6]. Nephrotoxicity occurs in one-third of 
patients and can be potentially severe or life-threatening. 
Moreover, these toxicities utilize substantial healthcare 
resources and thus an inexpensive, effective, prophylac-
tic protective strategy is of clear interest. Several oto- and 
nephroprotective approaches were developed (such as 
hydrating the patients during treatment, using less toxic 
cisplatin analogues) to avoid these reactions, including 
various chemoprotective agents used in experimental 
models (dimethylthiourea, melatonin, selenium, vitamin 
E, N-acetylcysteine [NAC], sodium thiosulfate) [5, 7–13].
N-Acetylcysteine is a sulfur-containing cysteine analog. 
It has been applied for decades as a mucolytic drug and 
as an antidote for acetaminophen overdose, as well as to 
prevent contrast-induced nephropathy (CIN) [14]. More 
recently, interest has been raised for the use of NAC in 
the prevention of cisplatin induced oto- and nephrotoxic-
ity. Interestingly, CIN from iodine-based contrast agents 
and cisplatin share common mechanistic features includ-
ing both intrinsic cellular- and inflammation-related 
ROS mediated cellular and stromal peroxidation damage 
[15–20]. The following properties of NAC are hypoth-
esized to be paramount for the prevention of oto- and 
nephrotoxicity: (1) NAC is thought to act as a vasodilator 
through nitric oxide effects, thus improving blood flow, 
(2) NAC is a precursor to GSH, the body’s endogenous 
ROS scavenger, (3) the antioxidant properties of NAC 
dampen inflammation caused by damage-associated 
molecular patterns that arise from biological macromol-
ecule peroxidation by ROS and cellular necrosis, and (4) 
NAC prohibits apoptosis and promotes cell survival by 
the activation of an extracellular signal-regulated kinase 
pathway [14]. When NAC enters the systemic circula-
tion it can only leave the blood vessels after N-deacety-
lation and subsequent carrier mediated active transport 
of l-cysteine by the alanine–serine–cysteine transporter 
(ASC-1) [21]. Once in the brain, l-cysteine may act as an 
antioxidant or can be converted to GSH. Our group and 
others have shown a low level delivery of radiolabeled 
NAC across the BBB [22–24]. We demonstrated that 
even at very high NAC concentration (1200 mg/kg) deliv-
ery was less than 0.5% of the administered dose per gram 
tissue after intravenous (IV) administration in rats, but 
was significantly enhanced by intra-arterial (IA) adminis-
tration [24]. It is possible that NAC is a ligand for ASC-1 
prior to deacetylation or that NAC is rapidly deacetylated 
in the blood and the observed radioactivity in the brain 
was due to radioactive cysteine. In the setting of inflam-
mation, oxidative stress could impair the BBB to increase 
NAC leak [22, 23]. In case of a brain tumor, vessels sup-
plying the tumor possess impaired barrier properties so 
both NAC and cisplatin can enter the tumor tissue to 
some degree.
A literature review revealed 38 trials evaluating NAC in 
the prevention of CIN, 15 with positive and 23 with nega-
tive outcomes, and 17 meta-analyses with conflicting 
conclusions [25]. There has been significant heterogene-
ity between studies due to various routes of administra-
tion and different dosages [25, 26]. Most trials followed 
Tepel’s regimen of 600  mg of NAC orally twice a day 
for 48 h and 0.45% saline intravenously, before and after 
injection of the contrast agent, or placebo and saline as 
control [26].
Similarly to CIN, NAC has demonstrated mixed results 
in the literature as an otoprotectant in the context of cis-
platin therapy [7, 14, 27–30]. Still, a handful of reports 
with positive results suggest otoprotective properties 
during cochlear insults through ROS mediated mecha-
nisms. Dosing, route, and timing of NAC administra-
tion seem to be important variables in NAC medicated 
Conclusions: In adults with kidney impairment, NAC can be safely given both IV and IA at a dose of 450 mg/kg. Addi-
tional studies are needed to confirm oto- and nephroprotective properties in the setting of cisplatin treatment.
Clinical Trial Registration URL: https://eudract.ema.europa.eu. Unique identifier: 2011-000887-92
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otoprotection. Whether or not NAC trafficking into the 
extravascular cochlear compartment occurs is an under-
studied question, and hence extravascular trafficking may 
not be required for otoprotective activity. NAC could 
potentially act by intravascular activity on ROS produc-
ing immune cells which can compromise blood-labyrinth 
barrier integrity and thus prevent enhanced cochlear 
uptake of cisplatin.
Preclinical ototoxicity studies demonstrated that IV 
or IA administration of NAC is required to achieve high 
blood concentration necessary for otoprotection [7, 8, 28, 
31]. As Stenstrom observed, oral NAC is cleared via the 
portal vein on the first pass through the liver, however 
31 of 38 reviewed trials ignored this first pass clearance 
and gave very small doses [14]. We assume that either 
the oral route or the applied low IV doses were likely a 
large factor in the negative results seen in previous clini-
cal trials. We hypothesized that NAC at high IV and IA 
(via the descending aorta) doses can be injected with an 
acceptable toxicity profile in children with malignant 
tumors. Our primary goal was to perform a dose escala-
tion study in pediatric patients. Due to rejection of our 
pediatric toxicity trial by the Institutional Review Board 
this phase I study used an adult population of subjects 
with stage 3 or worse kidney failure undergoing a radio-
logic procedure requiring iodine-based contrast media. 
Patients with renal failure were chosen with the thought 
that this population would be particularly sensitive to 
adverse events and thus the observed maximum toler-
ated dose (MTD) would include a large margin of safety 
when translated to the pediatric population. Using this 
study design we were also able to not only examine the 
chemoprotective properties of NAC, but could con-
firm its protection against CIN. The MTD will be evalu-
ated for efficacy in a future trial, specifically in pediatric 
populations.
Methods
Study protocol
This was a prospective, non-randomized, single center 
dose escalation trial of patients with stage 3 or worse 
chronic renal disease (glomerular filtration rate [GFR] 
< 60 mL/min/1.73 m2) who underwent a digital subtrac-
tion angiography (DSA) and/or vascular intervention 
with an isotonic nonionic contrast material (Iodixanol) 
between the years 2012 and 2015. Indication for the pro-
cedures was established by a vascular team including vas-
cular surgeons, interventional radiologists, and vascular 
physicians. Interventions were carried out according to 
international guidelines. Our primary objective was to 
establish the MTD of both IV and IA NAC. The second-
ary objective was to determine NAC pharmacology given 
IV or IA.
The study was approved by the Institutional Review 
Committee (12935-0/2011-EKL) and all subjects gave 
written informed consent.
Eligibility requirements
Patients between 18 and 85 years of age at risk for CIN 
were eligible to participate if they had stage 3 or worse 
kidney impairment (renal failure staging was deter-
mined by the following formula: Modification of Diet in 
Renal Disease, GFR ([mL/min/1.73 m2] = 175 × [Serum 
 creatinine]−1.154 × [Age]−0.203 × [0.742 if the subject was 
female]) with a life expectancy of 4 weeks from the date 
of registration [32].
Exclusion criteria
Subjects were excluded if they had acute kidney injury 
(e.g., significant change over 4  weeks), were on dialysis, 
had a systolic blood pressure of < 90 mmHg, had decom-
pensated heart failure at the time of admission, had a his-
tory of severe reactive airway disease, were at high risk 
for general anesthesia, were pregnant, had a positive 
serum human chorionic gonadotropin or was lactating, 
or who had contraindications to NAC or the contrast 
agent.
Treatment plan
Dose escalation
A group of three subjects was aimed to be evaluated at 
each of the following fixed dose levels of NAC: dose level 
1, 150 mg/kg/day; dose level 2, 300 mg/kg/day; dose level 
3, 600 mg/kg/day; dose level 4, 900 mg/kg/day; and dose 
level 5, 1200  mg/kg/day. The first dose level was based 
on the standard of care treatment of acetaminophen 
overdose [33]. The dose escalation was evaluated by the 
rate of grade 3 or 4 toxicities. In case of a severe toxic-
ity reaction an additional dose level was added. Toxicity 
was graded according to National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 
3.0. [34]. The dosing algorithm can be seen in Fig. 1. The 
NAC MTD was defined as one dose level below the dose 
that produced grade 3 or 4 toxicity.
Assignment for IV versus IA NAC
Patients were assigned to IV or IA using the last digit 
of their hospital identification number. Those with even 
last digits received IV NAC and those with odd last dig-
its received IA NAC. If the MTD was achieved for one 
group, all subsequent subjects were treated with the 
other regimen.
Premedication
Since it has been previously shown that NAC has 
dose dependent anaphylactoid reactions in 23–48% 
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of patients, all participants received premedication 
prior to NAC administration [35]. Premedication regi-
men consisted of 100  mg IV methylprednisolone and 
50 mg ranitidine 3 h prior to NAC, and 50 mg diphen-
hydramine 10  min prior to NAC. Additional doses of 
25  mg diphenhydramine were given 10  min after the 
start of the NAC infusion and repeated as clinically 
indicated.
Administration of the study drug
The study drug (Acetylcysteine [Fluimucil Antidote]) is 
available as a 20% solution in 25  mL (200  mg/mL) sin-
gle dose glass vials. The NAC was diluted to 150, 300, 
450, and 600  mg/kg in 250  mL of diluent (5% dextrose 
in water [Isodex]). The 900 and 1200 mg/kg doses were 
designed to be diluted in 500 mL of diluent. Each of the 
above dilutions were given either IV through a periph-
eral vein using an infusion pump (Alaris GH) or IA down 
the descending aorta through a fluid injection system 
(Medrad Avanta) over a period of 25–55  min. In the 
case of IV injection, the flow rate was 1000 mL/h. For IA 
administration a pigtail catheter was used (the tip of the 
catheter was positioned at the level of the renal arteries) 
and a pulsed infusion of 16.5 mL volume at 16.5 mL/sec 
was performed and repeated for a total of 15 injections. 
In the event of grade 1 or 2 toxicities the infusion rate 
was reduced.
Subject monitoring
Vital signs (pulse and respiration rate), blood pressure, 
electrical activity of the heart, and oxygen saturation 
were recorded by a cardiologist at baseline, prior to NAC 
infusion, every 10  min during infusion, and for 30  min 
after completion of NAC infusion. The patient was 
closely monitored for anaphylactoid reaction throughout 
the endovascular procedure in the angiogram suite and 
in the recovery unit after the DSA and/or intervention. In 
the recovery unit, fluid intake and output were measured 
for 2–4 h until the subject was sent to the ward.
Laboratory analysis of the blood samples
Blood samples were taken at baseline, prior to NAC, 
then 5 and 15 min after the NAC administration, as well 
as 24, 48, and 72  h following the radiologic procedure. 
Study drug and GSH levels were assessed prior to, then 
5 and 15 min after the completion of the study drug infu-
sion. Serum NAC and GSH analyses were done in our 
Research Laboratory using a high-performance liquid 
chromatography assay. Details of this procedure have 
been described previously [28].
Fig. 1 Dosing algorithm for N-acetylcysteine to determine the maximum tolerated dose in adults with chronic kidney disease. The N-acetylcysteine 
maximum tolerated dose was defined as one dose level below the dose that produced grade 3 or 4 toxicity. MTD maximum tolerated dose
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Statistical analysis
Statistical analysis was performed with SPSS 21.0 soft-
ware (IBM Corp., Armonk, NY) and SAS 9.4 software 
(SAS Institute Inc., Cary, NC). Continuous variables 
were expressed as means and standard deviations and 
were compared between two groups using the Students’ 
t test. A linear mixed-effects model was applied to evalu-
ate dose response relationships and differences at various 
time points for pharmacological factors while accounting 
for correlations among the multiple observations within 
the same patient. All analyses were two-tailed, and values 
of p ≤ 0.05 were considered statistically significant.
Results
Patient data
Twenty-eight subjects (13 women, 15 men; mean age: 
72.2  ±  6.8  years) were enrolled. Fifteen subjects had 
DSA (lower or upper extremity angiography, N  =  6; 
aortic arch and selective four-vessel cerebral angiogra-
phy, N =  3; lower extremity plus aortic arch and selec-
tive four-vessel cerebral angiography, N  =  3; renal 
angiography, N  =  3) while 12 underwent percutaneous 
transluminal angioplasty with or without stent place-
ment (internal carotid artery stenting, N = 4; renal artery 
stenting, N = 2; crural artery percutaneous transluminal 
angioplasty, N  =  2; subclavian artery stenting, N  =  1; 
common iliac artery stenting, N = 1; common iliac artery 
plus renal artery stenting, N  =  1; superficial femoral 
artery stenting, N = 1). One patient (7_IV) did not have 
radiologic intervention due to NAC-related acute severe 
toxicity.
N‑Acetylcysteine toxicity
The administered NAC volume and NAC infusion time 
did not differ significantly between the corresponding IV 
and IA groups (Table 1).
Maximum tolerated IV dose
Thirteen participants received IV NAC. Three patients 
completed dose level 1 and three completed dose level 
2 without having grade 3 or 4 toxicity. The first subject 
(7_IV) enrolled to dose level 3 developed rashes, flush-
ing, pruritus, and an intense bronchospasm immediately 
after completion of the study drug administration which 
Table 1 N-Acetylcysteine and  contrast agent volumes, N-acetylcysteine administration time, baseline serum creatinine 
levels, and 5-min N-acetylcysteine and glutathione concentrations
Italicized p-values indicate statistically significant values
IV intravenous, IA intra-arterial, SD standard deviation, NAC N-acetylcysteine, NA not applicable, CA contrast agent, GSH glutathione
Parameter NAC dose (mg/kg) IV group (Mean ± SD) IA group (Mean ± SD) p value
NAC volume (mL) 150 63.25 ± 50.61 51.88 ± 6.6 0.31
300 109.5 ± 6.89 132.5 ± 46.37 0.183
600 294 NA NA
450 167.58 ± 44.63 166.13 ± 41.61 0.956
NAC administration time (min) 150 26.67 ± 2.89 31.67 ± 7.53 0.196
300 31.67 ± 5.77 38.33 ± 2.89 0.173
600 51 NA NA
450 40 ± 6.32 42.5 ± 8.22 0.569
CA volume (mL) 150 94.33 ± 69.89 109.17 ± 56.16 0.768
300 80 ± 39.69 86.67 ± 64.29 0.887
600 0 NA NA
450 89.5 ± 15.86 88.5 ± 25.81 0.937
Baseline serum creatinine (μmol/L) 150 201 ± 11.97 118.17 ± 15.53 0.402
300 123.67 ± 33.23 160 ± 24.76 0.343
600 157 NA NA
450 209.33 ± 54.4 171.5 ± 52.89 0.486
NAC concentration at 5 min (mM) 150 0.43 ± 0.1 1.66 ± 0.32 < 0.001
300 1.04 ± 0.6 3.12 ± 0.77 0.023
600 4.53 NA NA
450 2.03 ± 0.95 4.1 ± 1.22 0.009
GSH concentration at 5 min (mM) 150 0.13 ± 0.16 0.2 ± 0.04 0.514
300 0.13 ± 0.03 0.96 ± 0.36 0.058
600 0.21 NA NA
450 0.19 ± 0.04 0.89 ± 0.31 0.003
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rapidly progressed to respiratory and cardiac arrest. Suc-
cessful cardiorespiratory resuscitation was performed 
according to the 2010 American Heart Association 
guidelines at which point the participant was trans-
ported to the intensive care unit where he was monitored 
for 3 days [36]. The patient left the hospital 6 days post 
NAC in good condition. Due to the serious toxicity in 
this subject, the protocol was modified and a new dose 
level of 450  mg/kg NAC was inserted between the 300 
and 600 mg/kg doses. Participants 8_IV, 9_IV, and 10_IV 
received 450 mg/kg dose of NAC. None had grade 3 or 
4 toxicity, therefore 450 mg/kg was considered to be the 
MTD and three additional patients were treated with the 
same dose in order to gain more data on NAC toxicity 
and pharmacokinetics (Fig. 2).
Maximum tolerated IA dose
Fifteen subjects received IA NAC. The first participant 
(1_IA) enrolled to the group developed an anaphylac-
tic reaction with life-threatening symptoms. She was 
treated according to the 2011 World Allergy Organization 
anaphylaxis guidelines in the angiogram suite and was 
transported to the intensive care unit where she was mon-
itored for 3 days [37]. The patient left the hospital 5 days 
post NAC infusion in good condition. The anaphylactic 
reaction occurred immediately after completion of the 
DSA. The time interval between the anaphylactic reac-
tion and NAC infusion was 1 h. The case was discussed 
by a multidisciplinary team which considered the adverse 
reaction to be a consequence of the contrast agent rather 
than NAC based on the elapsed time from the study drug 
infusion to the time of the anaphylactic reaction. Also, 
the subject provided information after the adverse reac-
tion that she developed hives on her chest 2 months pre-
viously after a cardiac catheterization. Furthermore, the 
cardiac catheterization was done in a different hospital, 
the hives were not mentioned in the final report, and the 
participant answered no for the question whether she 
had allergic reaction to anything in her life both prior to 
study enrollment and before the interventional procedure. 
Although two additional participants completed dose 
level 1 without having grade 3 or 4 toxicity, three more 
patients were treated with the same dose. Neither 300 nor 
450 mg/kg dose produced severe toxicity. The 450 mg/kg 
Fig. 2 Establishment of the maximum tolerated dose for N-acetylcysteine in adults with chronic kidney disease. Four hundred and fifty mg/kg 
N-acetylcysteine was found to be the maximum tolerated dose in both intravenous and intra-arterial groups. Asterisk: Adverse reaction to contrast 
agent rather than to N-acetylcysteine. IV intravenous, IA intra-arterial, MTD maximum tolerated dose
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dose was considered to be the MTD and three additional 
subjects received that dose (Fig. 2).
Minor toxicities
Grade 1 or 2 toxicities were seen in six participants 
(21.4%). Two-thirds of the minor toxicities occurred at 
a dose of 450  mg/kg NAC. All of them resolved either 
spontaneously or by giving appropriate treatment over 
30 min to 12 h following the toxicity (Table 2).
N‑Acetylcysteine pharmacokinetics
Results of the high-performance liquid chromatography 
analysis are summarized in Fig. 3.
Serum NAC levels
At baseline, NAC and GSH were not detected in the 
serum samples. Blood levels of NAC showed a significant 
linear dose response both 5 min (slope, 1.07 mM increase 
for every 150  mg/kg rise in NAC dose; p =  0.001) and 
Table 2 Toxicities attributed to N-acetylcysteine
NAC N-acetylcysteine, IV intravenous, IA intra-arterial
a Adverse reaction to contrast agent rather than to NAC
Group Patient number Weight (kg) NAC dose (mg/kg) NAC volume (mL) NAC toxicity
IV 4_IV 84 300 126 Grade 1, facial erythema
7_IV 98 600 294 Grade 4, respiratory and cardiac arrest
10_IV 96 450 216 Grade 2, pruritus and rash
11_IV 103 450 231.75 Grade 1, coughing
IA 1_IA 55 150 41.25 Grade  4a, anaphylaxis
8_IA 101 300 151.5 Grade 1, nausea
10_IA 95 450 213.75 Grade 1, coughing
11_IA 80 450 180 Grade 1, facial erythema
Fig. 3 N-Acetylcysteine pharmacokinetics: serum concentrations of N-acetylcysteine and glutathione at different dose levels and time intervals. 
Blood levels of N-acetylcysteine (upper row) showed a significant linear dose response, while gluthatione concentrations (lower row) were incon-
sistently elevated. IV intravenous, IA intra-arterial, NAC N-acetylcysteine, GSH glutathione
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15 min after IV administration (slope, 0.48 mM increase 
for every 150 mg/kg rise in NAC dose; p = 0.002). Simi-
lar significant linear dose responses were observed after 
IA injection with a slope of 1.22 mM for every 150 mg/
kg increase in NAC dose at 5 min (p < 0.001) and with a 
slope of 0.58 mM for every 150 mg/kg increase in NAC 
dose at 15  min (p =  0.005). In each group, NAC levels 
were nearly halved from 5 to 15  min post infusion. In 
particular, the overall mean NAC level was 1.63 mM (SE: 
0.23) and 0.81 mM (SE: 0.21), respectively, 5 and 15 min 
after IV administration; and 2.93  mM (SE: 0.22) and 
1.42  mM (SE: 0.15), respectively, 5 and 15  min after IA 
injection. At 5  min post infusion, NAC concentrations 
were significantly higher in the IA groups compared to 
the corresponding IV groups (p < 0.001; p = 0.023, p =   
0.009, respectively) (Table 1, Fig. 3).
Serum GSH levels
A significant linear dose response relationship was noted 
for GSH concentrations in the IV group. Since the rela-
tionships were similar at 5 and 15  min, an overall dose 
response relationship was estimated to yield a 0.37 mM 
increase in GSH values for every 150  mg/kg rise in 
NAC dose (p  <  0.001). In contrast to patients in the IV 
group, the overall dose response relationship was not sig-
nificantly linear in the IA group (p =  0.068). The mean 
GSH concentrations were higher in the IA than in the IV 
group (Table 1, Fig. 3).
Discussion
Our goal was to provide the MTD of NAC as a correct 
scientific basis for future efficacy trials, particularly in 
pediatric populations. Four hundred and fifty mg/kg 
NAC was found to be the MTD in this study, and we 
have shown that it can be given with an acceptable toxic-
ity both IV and IA in adults with impaired kidney func-
tion undergoing DSA with or without intervention. By 
determining the MTD we potentially gain the maximum 
concentration of NAC in the brain and cochlea to dimin-
ish the toxicity of agents like cisplatin, although the entry 
of NAC may be limited by the BBB and blood-labyrinth 
barrier.
A key factor in previous failed trials with NAC is that 
oral NAC is known to have 5–10% bioavailability in 
humans due to extensive first pass metabolism to GSH 
[38]. Oral NAC reaches a serum peak about an hour after 
ingestion and has an elimination half-life of 2.27 h [39]. 
Furthermore, there is no clear evidence that NAC effects 
are mediated indirectly by its metabolites.
The potential of oral NAC to be oto- and nephroprotec-
tive was examined in several preclinical studies. Dickey 
et al. determined in rats, that a single IV administration 
of 1500 mg/kg NAC is non-toxic, and three IV injections 
of 1200 mg/kg NAC, 4 h apart, are safe and well-tolerated 
[28]. In another study by Dickey et al. rats received NAC 
infusion at 100, 400 and 1200  mg/kg IV. Blood samples 
were taken 15  min post inoculation. Another group of 
rats was given NAC 1200 mg/kg orally, with blood sam-
ples collected after 15 and 60 min. Total NAC concentra-
tions were analyzed and similarly to our findings, blood 
levels of NAC showed a rough linear dose response after 
IV administration of NAC. In contrast to the IV results, 
the group given NAC 1200 mg/kg by the oral route had 
very low levels of serum NAC [28]. In their third study, 
rats were treated with cisplatin 10  mg/kg intraperito-
neally 30  min after NAC 400  mg/kg given by intraperi-
toneal, oral, or IV routes, compared with cisplatin alone. 
NAC was chemoprotective against the cisplatin nephro-
toxicity, depending on the route of administration. Rats 
receiving NAC IV had very low blood urea nitrogen 
levels 3 days post treatment. In the case of oral or intra-
peritoneal NAC administration, the blood urea nitrogen 
concentrations were as high as in the group of rats who 
did not get NAC [28]. In their fourth study, rats were 
treated with cisplatin 10 mg/kg intraperitoneally 30 min 
after NAC 50  mg/kg infused IV or IA. The blood urea 
nitrogen levels were significantly lower in the IA group—
the blood urea nitrogen levels were similar to those when 
NAC was injected IV at high dose (400 mg/kg)—indicat-
ing a significantly reduced rate of nephrotoxicity for the 
IA delivery [28]. Assuming that this rat chemoprotec-
tive model represents the effects of cisplatin as those of 
contrast agents in humans, these observations call into 
question if oral NAC or low dose IV NAC has any clinical 
impact on cisplatin induced oto- and nephrotoxicity.
Briguori et al. and Marenzi et al. were the only investi-
gators who made dose comparisons in humans. Briguori 
et  al. compared single dose NAC 600  mg orally twice a 
day for 48 h with double dose NAC 1200 mg (17.1 mg/kg 
for a 70 kg subject) orally twice a day for 48 h. Although 
these doses were not high and were given orally, the out-
come was favorable for the double dose [40]. Marenzi 
et al. compared two IV doses (600 and 1200 mg total dose 
per patient) prior to the angioplasty and two oral doses 
(600 and 1200 mg twice a day for 48 h) after the proce-
dure with placebo. A greater increase in serum creatinine 
was observed in the placebo group compared to patients 
treated with NAC and the higher NAC IV dose was even 
better than the lower dose, which implies that NAC 
actions may be dose dependent [41]. These observations 
are in line with the findings of the above mentioned rat 
studies and demonstrate the importance of this phase I 
trial.
It is also worth considering that the route of NAC 
administration markedly affects its biodistribution. In 
an animal study performed by our group, we found that 
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when radiolabeled NAC was administered IA into the 
right carotid artery of the rat, high levels of radiolabel 
were found throughout the right cerebral hemisphere, 
regardless of whether or not the BBB was opened. Deliv-
ery was 0.41% of the injected dose, comparable to the 
levels found in the liver (0.57%) and kidney (0.70%). In 
contrast, the aortic infusion above the renal arteries pre-
vented the brain delivery and changed the biodistribu-
tion of NAC. The change in tissue delivery with different 
modes of administration is likely due to NAC being dea-
cetylated and the amino acid cysteine is rapidly bound by 
tissues via the amino acid transporters [24].
The limitations of our study include the special sub-
ject population: all patients were older than 50 years, had 
impaired kidney function, and atherosclerotic disease. 
Although serum creatinine values were measured both 
before and after contrast agent administration additional 
trials should be performed to determine whether either 
IV or IA 450  mg/kg NAC is protective against CIN or 
chemoprotective against cisplatin in pediatric subjects.
Conclusions
In conclusion, we found that NAC can be safely given 
both IV and IA at a dose of 450  mg/kg in adults with 
reduced renal function. Phase II and III studies are 
needed to determine whether high IV and IA doses can 
avoid oto- and nephrotoxicity of platinum-based chemo-
therapy, and if yes, whether a particular route of admin-
istration of NAC provides improved chemoprotection. A 
considerable hurdle with NAC is disentangling the mixed 
results from studies utilizing oral NAC administration; 
we advocate for careful analysis and comparison of oral 
route trials in humans with those of IV or IA. A phase 
I trial in children is currently underway with different 
doses of NAC after cisplatin to prevent ototoxicity (clini-
caltrials.gov NCT02094625).
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